Oncology

Coeptis Therapeutics Enters into Exclusive Option Agreement with University of Pittsburgh for Rights to CAR-T Technologies Designed to Target Multiple Cancer Indications, Including Hematologic and Solid Tumors

05/20/2022

Option agreement comprises three technologies and associated patent portfolios Announcement marks the third strategic agreement for Coeptis this quarter designed to bolster its portfolio and complement its innovative cell therapy platforms Excerpt from the Press Release: WEXFORD, Pa., May 17, 2022 /PRNewswire/ — Coeptis Therapeutics, Inc. (OTC PINK: COEP) (“Coeptis” or “the Company”), a biopharmaceutical company developing…

Read More

Black Diamond Therapeutics Announces Publication of New Computational and Functional Analyses of HER2 Mutations Based on its Proprietary MAP Discovery Engine

05/19/2022

– Peer-reviewed publication highlights 22 new oncogenic HER2 driver mutations identified and experimentally validated with MAP discovery engine – Excerpt from the Press Release: CAMBRIDGE, Mass. and NEW YORK, May 12, 2022 (GLOBE NEWSWIRE) — Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a precision oncology medicine company pioneering the discovery and development of MasterKey therapies, today…

Read More

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

05/19/2022

Excerpt from the Press Release: WATERTOWN, Mass., May 16, 2022 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science to develop a new generation of small-molecule medicines and transform how disease is treated, today announced that the first patient has been dosed in its…

Read More

Elicio Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate ELI-002 in Combination with Libtayo® (cemiplimab) in KRAS-Driven Tumors

05/18/2022

The ELI-002 and Libtayo® combination will be studied in KRAS-driven tumors including Stage III and IV non-small cell lung cancer (NSCLC), Stage IV colorectal cancer (CRC) and unresectable, locally advanced or oligometastatic pancreatic ductal adenocarcinoma (PDAC) Excerpt from the Press Release: BOSTON, May 16, 2022 (GLOBE NEWSWIRE) — Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline…

Read More

NGM Bio Announces Initiation of Phase 1/1b Clinical Study of NGM438 for the Treatment of Patients with Advanced Solid Tumors

05/18/2022

–Dose-escalation and dose-expansion trial will evaluate the potential of NGM438, a LAIR1 antagonist antibody product candidate, as a monotherapy and in combination with KEYTRUDA®— –All three of NGM Bio’s wholly-owned myeloid reprogramming product candidates –NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831, an ILT3 antagonist antibody, and NGM438 – are now in the clinic–…

Read More

Predicting cancer evolution with deep learning algorithms

05/17/2022

New proof-of-concept approach offers faster, more accurate inferences about tumour populations. Excerpt from the Press Release: The prevalence of mutations in a tumour can provide clues about how the cancer has grown or evolved and how best to treat it. But making predictions about the evolution of mutated tumours using a single DNA sequenced biopsy…

Read More

Rocket VR Announces New Study Exploring The Impact of Virtual Reality Therapeutics on Chronic Pain in Cancer Patients

05/16/2022

Research with renowned oncology expert Dr. Linda Carlson will assess feasibility of a virtual reality guided mindfulness program Excerpt from the Press Release: BOSTON, May 5, 2022 /PRNewswire/ — Rocket VR Health, a digital therapeutics company developing immersive therapy programs, is pleased to announce a new study in partnership with Dr. Linda Carlson, Enbridge Research Chair…

Read More

Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors

05/13/2022

Clinical program advancement represents key milestone for Aulos as a clinical-stage company and AU-007’s potential as a novel cancer treatment Excerpt from the Press Release: LARKSPUR, Calif.–(BUSINESS WIRE)–Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through the development of potentially best-in-class IL-2 therapeutics, today announced it has dosed the first patient in a…

Read More

Turning Point Therapeutics Announces Pipeline Expansion, Licensing of TPX-4589 (LM-302), A Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate for Gastrointestinal Cancers, From Lanova Medicines

05/12/2022

Strategic Expansion of Turning Point Precision Oncology Portfolio TPX-4589 (LM-302) Currently in Two Ongoing Phase 1 Studies Agreement Includes Potential Broader Scope to Collaborate on up to Three Additional ADC Programs Excerpt from the Press Release: SAN DIEGO, May 05, 2022 (GLOBE NEWSWIRE) — Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a clinical-stage precision oncology company…

Read More

ChristianaCare Scientists Show for the First Time That Tumor Cells Can Manipulate the Body’s Natural Antibody Response to Triple Negative Breast Cancer

05/09/2022

Findings point to potential new therapeutic targets for this highly aggressive, drug-resistant breast cancer subtype Excerpt from the Press Release: In breakthrough research at ChristianaCare’s Helen F. Graham Cancer Center & Research Institute, scientists have discovered that a protein secreted by tumor cells can switch off the body’s natural defenses against triple negative breast cancer (TNBC).…

Read More